
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Auto Immun Highlights</journal-id><journal-id journal-id-type="iso-abbrev">Auto Immun Highlights</journal-id><journal-title-group><journal-title>Auto-Immunity Highlights</journal-title></journal-title-group><issn pub-type="ppub">2038-0305</issn><issn pub-type="epub">2038-3274</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29845583</article-id><article-id pub-id-type="pmc">5975024</article-id><article-id pub-id-type="publisher-id">106</article-id><article-id pub-id-type="doi">10.1007/s13317-018-0106-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nalli</surname><given-names>Cecilia</given-names></name><address><email>cecilianalli2@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Somma</surname><given-names>Valentina</given-names></name><address><email>v.somma@medipan.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Andreoli</surname><given-names>Laura</given-names></name><address><email>laura.andreoli@unibs.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000fc;ttner</surname><given-names>Thomas</given-names></name><address><email>thomas.buettner@genericassays.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schierack</surname><given-names>Peter</given-names></name><address><email>peter.schierack@b-tu.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mahler</surname><given-names>Michael</given-names></name><address><email>mmahler@inovadx.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6861-6827</contrib-id><name><surname>Roggenbuck</surname><given-names>Dirk</given-names></name><address><email>dirk.roggenbuck@b-tu.de</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tincani</surname><given-names>Angela</given-names></name><address><email>angela.tincani@unibs.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000417571846</institution-id><institution-id institution-id-type="GRID">grid.7637.5</institution-id><institution>University of Brescia, </institution></institution-wrap>Brescia, Italy </aff><aff id="Aff2"><label>2</label>Research and Development Department, Medipan GmbH, Dahlewitz, Berlin, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.452429.c</institution-id><institution>Research and Development Department, </institution><institution>GA Generic Assays GmbH, </institution></institution-wrap>Dahlewitz, Berlin, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2188 0404</institution-id><institution-id institution-id-type="GRID">grid.8842.6</institution-id><institution>Institute of Biotechnology, Faculty Environment and Natural Sciences, </institution><institution>Brandenburg University of Technology Cottbus-Senftenberg, </institution></institution-wrap>Universit&#x000e4;tsplatz 1, 01968 Senftenberg, Germany </aff><aff id="Aff5"><label>5</label>Inova Diagnostics, San Diego, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2018</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>6</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Anti-phospholipid antibodies (aPL) analyzed by line immunoassay (LIA) can recognize beta<sub>2</sub>-glycoprotein I (&#x003b2;<sub>2</sub>GPI) domain 1 (D1) epitopes depending on &#x003b2;<sub>2</sub>GPI binding to distinct phospholipids. The aPL LIA was compared with consensus ELISA to investigate whether both techniques can discriminate anti-phospholipid syndrome (APS) patients from aPL-positive, systemic autoimmune rheumatic diseases (SARD) patients without clinical symptoms of APS and controls.</p></sec><sec><title>Methods</title><p id="Par2">Thirty-four APS patients (14 arterial/venous thrombosis, 16 pregnancy morbidity, and 4 both), 41 patients with SARD lacking clinical APS criteria but demonstrating positivity for anti-&#x003b2;<sub>2</sub>GPI (a&#x003b2;<sub>2</sub>GPI) IgG, and 20 healthy subjects (HS) were tested for aPL to cardiolipin (aCL), phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol (aPG), phosphatidylinositol, phosphatidylserine, &#x003b2;<sub>2</sub>GPI, prothrombin, and annexin V by LIA. Samples were also tested for aCL, a&#x003b2;<sub>2</sub>GPI, a&#x003b2;<sub>2</sub>GPI-domain 1 (aD1), and a&#x003b2;<sub>2</sub>GPI-domains 4&#x02013;5 (aD4&#x02013;5) by ELISA and for lupus anti-coagulant.</p></sec><sec><title>Results</title><p id="Par3">Comparison of LIA with ELISA revealed a good agreement for the consensus criteria aPL a&#x003b2;<sub>2</sub>GPI and aCL IgG (kappa&#x02009;=&#x02009;0.69, 0.68, respectively) and a moderate agreement for IgM (kappa&#x02009;=&#x02009;0.52, 0.49, respectively). Regarding ELISA, aD1/aD4&#x02013;5 demonstrated the best performance of differentiating APS from asymptomatic SARD [area under the curve (AUC): 0.76]. aPG IgG had the best performance by LIA (AUC: 0.72) not significantly different from aD1/aD4&#x02013;5. There was a good agreement for aPG IgG with aD1/aD4&#x02013;5 (kappa&#x02009;=&#x02009;0.71).</p></sec><sec><title>Conclusions</title><p id="Par4">aD1/aD4&#x02013;5 (ELISA) and aPG IgG (LIA) differentiate APS from SARD patients. PG appears to interact with &#x003b2;<sub>2</sub>GPI of APS patients and exposes D1 thereof for disease-specific aPL binding in LIA.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Anti-phospholipid syndrome</kwd><kwd>Beta2 glycoprotein I</kwd><kwd>Anti-phospholipid antibody</kwd><kwd>Domain 1</kwd><kwd>Phosphatidylglycerol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Anti-phospholipid syndrome (APS) is an autoimmune disorder, clinically characterized by arterial and/or venous thrombosis as well as pregnancy-related complications [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The APS can be primary or secondary, depending on the absence or presence of any other related systemic autoimmune rheumatic disease (SARD) such as, e.g., systemic lupus erythematosus (SLE). The APS could be associated with a high risk of death in the rare catastrophic anti-phospholipid syndrome, a rapid and simultaneous multi-organ failure due to generalized thrombosis [<xref ref-type="bibr" rid="CR3">3</xref>]. Apart from one clinical criterion (vascular thrombosis and/or adverse obstetric event), the revised classification criteria require the persistent detection of anti-phospholipid antibodies (aPL) such as anti-beta<sub>2</sub> glycoprotein I (a&#x003b2;<sub>2</sub>GPI), anti-cardiolipin (aCL), and/or autoantibodies interfering with coagulation [lupus anti-coagulant (LAC)] for the diagnosis of APS.</p><p id="Par6">The recommended method to detect a&#x003b2;<sub>2</sub>GPI and aCL is the enzyme-linked immunosorbent assay (ELISA) using a polystyrene solid phase for autoantigen immobilization. However, aPL testing by ELISA still represents a challenge because of the difficulties in the inter- and intra-assay reproducibility [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, a&#x003b2;<sub>2</sub>GPI antibodies detected by ELISA have been reported in healthy adults and children. These data support the hypothesis that &#x0201c;innocent&#x0201d;, non-disease associated aPL could exist, too [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The subgroup of pathogenic a&#x003b2;<sub>2</sub>GPI antibodies seems to be mainly directed versus domain 1 (D1) and not to domains 4 and 5 (D4&#x02013;5), and their pathogenicity appears to be dependent on their Fc glycosylation [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Indeed, the former are involved in thrombotic events characteristic of APS, whereas the latter do not interfere with the coagulation process, neither are they associated with other clinical APS manifestations [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par7">New assay techniques based on chemiluminescence (CIA) or fluorescence enzyme immunoassays for the detection of APS-specific aPL have emerged [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Especially, the CIA system has been shown to reduce the inter-laboratory variability [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par8">Of note, a novel line immunoassay (LIA) offering the opportunity to test for several aPL has been reported [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. This LIA appeared to detect preferably aPL to D1 (aD1) of the patient&#x02019;s &#x003b2;<sub>2</sub>GPI bound to distinct negatively charged phospholipids. Furthermore, aPL not related to a&#x003b2;2GPI were detected, too [<xref ref-type="bibr" rid="CR16">16</xref>]. Altogether, the former and these &#x0201c;non-criteria&#x0201d; IgG and IgM aPL to phosphatidylserine (aPS), phosphatidylinositol (aPI), phosphatidylcholine (aPC), phosphatidylethanolamine (aPE), phosphatidic acid (aPA), phosphatidylglycerol (aPG), annexin V (aAnV), and prothrombin (aPT) could be used for aPL profiling and might be helpful in the clinical differentiation of APS patients [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Nevertheless, the clinical meaning of &#x0201c;non-criteria&#x0201d; antibodies is still debated and &#x003b2;<sub>2</sub>GPI is generally accepted as the major autoantigenic target recognized by APS-specific aPL [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par9">The novel LIA used a hydrophobic membrane for the immobilization of different phospholipids and co-factors [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In particular, negatively charged phospholipids could bind the patient&#x02019;s own &#x003b2;2GPI which in turn interacted with APS-specific aD1. Thus, the specificity of this new multiplex reaction environment was reported to be superior to aPL consensus ELISA [<xref ref-type="bibr" rid="CR23">23</xref>]. In a recent study comparing aPL testing by LIA with ELISA in APS patients, asymptomatic aPL-positive carriers, and infectious patients, the LIA demonstrated a better specificity, too [<xref ref-type="bibr" rid="CR16">16</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Preferential binding of anti-phospholipid antibodies (aPL) to domain 1 (D1) of patient&#x02019;s beta2-glycoprotein I (&#x003b2;<sub>2</sub>GPI) in the line immunoassay (LIA). In contrast to the planar solid phase used in enzyme immunoassays, the porous hydrophobic LIA membrane incorporates the hydrophobic phospholipid (PL)-tail during immobilization. This shields the by far larger tail of the amphiphatic PL molecule from the reaction environment and, thus, prevents unspecific interactions. Number, orientation, and accessibility of anionic phosphate groups of the differing hydrophilic PL heads may influence the binding of the patient&#x02019;s &#x003b2;<sub>2</sub>GPI (<bold>a</bold>) and consequently of the &#x003b2;<sub>2</sub>GPI-dependent aPL (<bold>c</bold>). After binding of &#x003b2;<sub>2</sub>GPI to the immobilized anionic PL by domain 5 (D5, containing the PL-binding site), D1 forms the accessible top of the induced fish-hook-like &#x003b2;<sub>2</sub>GPI structure (<bold>b</bold>). Due to the high density of negatively charged PL heads on the membrane, the formation of a &#x003b2;<sub>2</sub>GPI layer with a unique D1 epitope structure is assumed. The layer formation seems to hinder aPL binding to &#x003b2;<sub>2</sub>GPI epitopes close to D5 [<xref ref-type="bibr" rid="CR16">16</xref>]</p></caption><graphic xlink:href="13317_2018_106_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par10">The appearance of aPL in SARD patients without characteristic clinical signs of APS is poorly understood yet. Thus, we wondered whether aPL detected by LIA or consensus criteria ELISA could discriminate primary APS from SARD without clinical symptoms of APS.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and control subjects</title><p id="Par11">Thirty-four patients with primary APS including 14 with arterial and/or venous thrombosis, 16 females with obstetric APS suffering from pregnancy-related complications, and 4 having both clinical symptoms were diagnosed by characteristic international clinical and serological consensus criteria (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The patients were selected from a cohort routinely followed at the university hospital in Brescia. All patients demonstrated elevated levels of a&#x003b2;<sub>2</sub>GPI IgG antibodies by an in-house ELISA. This inclusion criterion was chosen to study the specificity of these antibodies against different &#x003b2;<sub>2</sub>GPI domains.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic, clinical, and laboratory baseline characteristics of the 75 anti-beta<sub>2</sub> glycoprotein I (a&#x003b2;<sub>2</sub>GPI) IgG-positive patients and 20 healthy subjects (children)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Primary thrombotic or obstetric APS (<italic>n</italic>&#x02009;=&#x02009;34)</th><th align="left">SARD (<italic>n</italic>&#x02009;=&#x02009;41)</th><th align="left">Healthy subjects (<italic>n</italic>&#x02009;=&#x02009;20)</th></tr></thead><tbody><tr><td align="left">Sex, no. (%) female</td><td align="left">31/34 (91%)</td><td align="left">36/41 (88%)</td><td align="left">9/20 (55%)</td></tr><tr><td align="left">Autoimmune disease</td><td align="left">34/34 (100%)</td><td align="left">41/41 (100%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;Primary APS</td><td align="left">34/34 (100%)</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;SLE</td><td align="left">0 (0%)</td><td align="left">11/41 (27%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;SSj</td><td align="left">0 (0%)</td><td align="left">2/41 (5%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;SLE&#x02009;+&#x02009;SSj</td><td align="left">0 (0%)</td><td align="left">3/41 (7%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;DLE</td><td align="left">0 (0%)</td><td align="left">1/41 (2%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;PBC</td><td align="left">0 (0%)</td><td align="left">3/41 (7%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;SSc</td><td align="left">0 (0%)</td><td align="left">2/41 (5%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;DM/PM</td><td align="left">0 (0%)</td><td align="left">4/41 (10%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;UCTD</td><td align="left">0 (0%)</td><td align="left">15/41 (37%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;Thrombosis</td><td align="left">19/34 (56%)</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Arterial</td><td align="left">7/19 (37%)</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Venous</td><td align="left">12/19 (63%)</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">&#x000a0;Obstetric manifestations</td><td align="left">20/34 (59%)</td><td align="left">0 (0%)</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;&#x000a0;Pregnancy loss</td><td align="left">15/20 (75%)</td><td align="left">0 (0%)</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;&#x000a0;Preeclampsia</td><td align="left">5/20 (25%)</td><td align="left">0 (0%)</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Laboratory features</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;LAC positivity</td><td align="left">24/34 (71%)</td><td align="left">18/41 (44%)</td><td align="left">NP</td></tr><tr><td align="left">&#x000a0;&#x000a0;a&#x003b2;<sub>2</sub>GPI IgG, median OD (25&#x02013;75th percentile)</td><td align="left">1.470 (0.929&#x02013;1.747)</td><td align="left">1.004 (0.655&#x02013;1.298)</td><td align="left">0.139 (0.047&#x02013;0.444)</td></tr><tr><td align="left">&#x000a0;&#x000a0;a&#x003b2;<sub>2</sub>GPI IgM, median OD (25&#x02013;75th percentile)</td><td align="left">0.350 (0.165&#x02013;0.576)</td><td align="left">0.450 (0.202&#x02013;0.838)</td><td align="left">0.088 (0.049&#x02013;0.132)</td></tr></tbody></table><table-wrap-foot><p><italic>APS</italic> anti-phospholipid syndrome, <italic>aCL</italic> anti-cardiolipin antibodies, <italic>DLE</italic> discoid lupus erythematosus, <italic>DM</italic>/<italic>PM</italic> dermato/polymyositis, <italic>LAC</italic> lupus anti-coagulant, <italic>NA</italic> not applicable, <italic>NP</italic> not performed, <italic>OD</italic> optical density, <italic>PBC</italic> primary biliary cirrhosis, <italic>SARD</italic> systemic autoimmune rheumatic disease, <italic>SLE</italic> systemic lupus erythematosus, <italic>SSc</italic> systemic scleroderma, <italic>SjS</italic> Sj&#x000f6;gren syndrome, <italic>UCTD</italic> undifferentiated connective tissue disease</p></table-wrap-foot></table-wrap>
</p><p id="Par12">As disease controls, 41 patients with SARD and no anamnestic thrombotic and adverse pregnancy events but positivity for a&#x003b2;<sub>2</sub>GPI IgG [11 with SLE, 2 with systemic sclerosis (SSc), 2 with Sj&#x000f6;gren syndrome (SjS), 3 with SLE and secondary SjS, 15 with undifferentiated connective tissue disease (UTCD), 1 with discoid lupus erythematosus (DLE), 4 with dermato/polymyositis (DM/PM), and 3 patients with primary biliary cholangitis (PBC)] were enrolled. This group was chosen due to the comparability with the disease group. Furthermore, 20 healthy subjects (children) (HS) were included as non-diseased controls. All children were aPL negative. The study was approved by the local ethical committee after a written informed consent from each patient. All sera were stored at &#x02212; 20&#x000a0;&#x000b0;C.</p></sec><sec id="Sec4"><title>ELISA for the detection of antibodies to cardiolipin and &#x003b2;<sub>2</sub>GPI</title><p id="Par13">To detect classification criteria IgG and IgM antibodies to CL and &#x003b2;<sub>2</sub>GPI in the patient sera, commercially available solid-phase ELISAs employing purified human &#x003b2;<sub>2</sub>GPI in complex with CL and human &#x003b2;<sub>2</sub>GPI alone were used, respectively (GA Generic Assays GmbH, Dahlewitz, Germany). Assessment of aPL antibodies was conducted according to the instructions of the manufacturer [<xref ref-type="bibr" rid="CR21">21</xref>]. The sera with a concentration equal or more than 10&#x000a0;U/mL for IgG and IgM, respectively, was considered positive. The same serum samples were also analyzed by in-house assays and the results were comparable with the commercial ELISA (data not shown).</p><p id="Par14">Research ELISAs for aD1 and aD4&#x02013;5 IgG developed by Inova Diagnostics (San Diego, US) were performed as previously described [<xref ref-type="bibr" rid="CR9">9</xref>]. A ratio of aD1 and aD4&#x02013;5 with a cutoff of 1.5 was used to test sera for aPL positivity.</p></sec><sec id="Sec5"><title>LAC testing</title><p id="Par15">The analysis of lupus anti-coagulant (LAC) was performed according to the international recommendations [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, the LAC testing comprised a three-step procedure:<list list-type="bullet"><list-item><p id="Par16">Demonstration of a prolonged phospholipid-dependent clotting time as screening test of hemostasis by dilute Russell viper venom time (dRVVT) or activated partial thromboplastin time (aPTT or lupus aPTT) analysis.</p></list-item><list-item><p id="Par17">Mixing patient plasma with normal plasma fails to correct the prolonged screening test(s).</p></list-item><list-item><p id="Par18">Addition of excess phospholipid shortens or corrects the prolonged coagulation test (demonstration of phospholipid dependence).</p></list-item></list>
</p></sec><sec id="Sec6"><title>Line immunoassay for the detection of aPL antibodies</title><p id="Par19">Antibodies to CL, PA, PC, PE, PG, PI, PS, the protein co-factors &#x003b2;<sub>2</sub>GPI, AnV, and PT were detected using a commercially available LIA according to the recommendations of the manufacturer (GA Generic Assays GmbH) [<xref ref-type="bibr" rid="CR16">16</xref>]. Processed LIA strips were read out densitometrically employing a scanner with the evaluation software Dr. Dot Line Analyzer (GA Generic Assays GmbH) and a grayscale calibration card for standardization. The grayscale calibration card was provided on the template of the kit. Values were read off as optical density (OD) units and OD values equaling or above 50 were scored positive. This cutoff was determined by calculating the 99th percentile of 150 apparently healthy individuals as recommended by the international classification criteria for aPL testing and Clinical and Laboratory Standards Institute (CLSI) guideline C28-A3 [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par20">Fisher&#x02019;s exact test was performed with two-tailed probability to detect the differences between groups as appropriate using Medcalc statistical software (Medcalc, Mariakerke, Belgium). Inter-rater agreement statistics ware applied for within-group comparison. The two-tailed, Kruskal&#x02013;Wallis test was used to test for statistically significant differences of independent samples. <italic>p</italic> values of less 0.05 were considered significant.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Comparison of aPL analysis by ELISA and LIA</title><p id="Par21">To identify the aPL antibody profiles by ELISA and LIA, we tested 34 sera from patients with APS and 61 controls including 41 asymptomatic patients suffering from SARD and 20 HS (Table<xref rid="Tab2" ref-type="table">2</xref>). Comparative analysis of the consensus criteria aPL aCL and a&#x003b2;<sub>2</sub>GPI in 95 sera detected by LIA and ELISA demonstrated good agreement for IgG [kappa&#x02009;=&#x02009;0.69, 95% confidence interval (CI) 0.55&#x02013;0.84; 0.68, 95% CI 0.54&#x02013;0.83, respectively] and moderate concordance for IgM (kappa&#x02009;=&#x02009;0.52, 95% CI 0.35&#x02013;0.69; 0.49, 95% CI 0.32&#x02013;0.66, respectively). There was a significant difference according to McNemar&#x02019;s test for aCL and a&#x003b2;<sub>2</sub>GPI IgM (difference: 15.8 and 13.7%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively), whereas the corresponding IgG analyses did not reveal a significant difference for both methods. The consensus ELISA testing for aCL and a&#x003b2;<sub>2</sub>GPI is not significantly more specific than aPL analysis by LIA covering 10 aPL with regard to the false positives in HS (1/20 vs 3/20, <italic>p</italic>&#x02009;=&#x02009;0.605).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Anti-phospholipid antibody (aPL) positives by line immunoassay (LIA) and consensus criteria enzyme-linked immunosorbent assay (ELISA) in 95 subjects including 34 patients with anti-phospholipid syndrome (APS), 41 with systemic autoimmune rheumatic disease (SARD), and 20 healthy subjects (children) (HS) as control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6">ELISA</th><th align="left" rowspan="3">LAC</th><th align="left" rowspan="3">TP</th><th align="left" rowspan="3">aD1/aD4&#x02013;5</th><th align="left" colspan="21">LIA</th></tr><tr><th align="left" rowspan="2"/><th align="left" colspan="2">ACL</th><th align="left" colspan="2">a&#x003b2;<sub>2</sub>GPI</th><th align="left" rowspan="2">Any aPL</th><th align="left" colspan="2">aCL</th><th align="left" colspan="2">aPA</th><th align="left" colspan="2">aPC</th><th align="left" colspan="2">aPE</th><th align="left" colspan="2">aPG</th><th align="left" colspan="2">aPI</th><th align="left" colspan="2">aPS</th><th align="left" colspan="2">aAnV</th><th align="left" colspan="2">a&#x003b2;<sub>2</sub>GPI</th><th align="left" colspan="2">aPT</th><th align="left" rowspan="2">Any aPL</th></tr><tr><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th><th align="left">G</th><th align="left">M</th></tr></thead><tbody><tr><td align="left">APS<break/><italic>n</italic>&#x02009;=&#x02009;34</td><td align="left">24</td><td align="left">21</td><td align="left">30</td><td align="left">18</td><td align="left">31</td><td align="left">24</td><td align="left">14</td><td align="left">28</td><td align="left">27</td><td align="left">13</td><td align="left">24</td><td align="left">10</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">18</td><td char="." align="char">1</td><td align="left">7</td><td char="." align="char">2</td><td align="left">30</td><td align="left">16</td><td char="." align="char">2</td><td char="." align="char">5</td><td align="left">27</td><td align="left">17</td><td align="left">17</td><td char="." align="char">5</td><td align="left">33</td></tr><tr><td align="left">SARD<break/><italic>n</italic>&#x02009;=&#x02009;41</td><td align="left">18***</td><td align="left">19</td><td align="left">25**</td><td align="left">23</td><td align="left">33</td><td align="left">18***</td><td align="left">8</td><td align="left">26</td><td align="left">26</td><td align="left">12</td><td align="left">22</td><td align="left">8</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">4*</td><td char="." align="char">0</td><td align="left">3</td><td char="." align="char">2</td><td align="left">27***</td><td align="left">9***</td><td char="." align="char">0</td><td char="." align="char">3</td><td align="left">22***</td><td align="left">12</td><td align="left">7**</td><td char="." align="char">3</td><td align="left">32</td></tr><tr><td align="left">HS<break/><italic>n</italic>&#x02009;=&#x02009;20</td><td align="left">NA</td><td align="left">0<sup>#</sup></td><td align="left">0<sup>#</sup></td><td align="left">1<sup>##</sup></td><td align="left">1<sup>#</sup></td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">1<sup>#</sup></td><td align="left">0<sup>##</sup></td><td align="left">0<sup>#</sup></td><td align="left">0<sup>####</sup></td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td align="left">0<sup>#</sup></td><td char="." align="char">1</td><td align="left">0<sup>####</sup></td><td char="." align="char">0</td><td align="left">0<sup>#</sup></td><td align="left">0<sup>##</sup></td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left">1<sup>#</sup></td><td align="left">0<sup>#</sup></td><td align="left">1<sup>##</sup></td><td char="." align="char">1</td><td align="left">3<sup>#</sup></td></tr></tbody></table><table-wrap-foot><p>Comparison of APS vs SARD: *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>Comparison of APS vs HC: <sup>#</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <sup>###</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>####</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>LAC and TP testing was conducted for 33 APS and 39 SARD patients only</p><p><italic>a</italic>&#x003b2;<sub><italic>2</italic></sub><italic>GPI</italic> anti-beta<sub>2</sub> glycoprotein I, <italic>aCL</italic> anti-cardiolipin, <italic>aD1</italic> anti-domain 1, <italic>aD4</italic>&#x02013;5 anti-domains 4 and 5, <italic>aPA</italic> anti-phosphatidic acid, <italic>aPC</italic> anti-phosphatidylcholine, <italic>aPE</italic> anti-phosphatidylethanolamine, <italic>aPG</italic> anti-phosphatidylglycerol, <italic>aPI</italic> anti-phosphatidylinositol, <italic>aPS</italic> anti-phosphatidyl-serine, <italic>aAnV</italic> anti-annexin V, <italic>aPT</italic> anti-prothrombin, <italic>LAC</italic> lupus anti-coagulant, <italic>TP</italic> triple positivity (aCL positive, <italic>a</italic>&#x003b2;<sub><italic>2</italic></sub><italic>GPI</italic> positive, LAC positive), <italic>NA</italic> not available</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Comparison of aPL testing in APS patients and healthy controls</title><p id="Par22">Both LIA and ELISA showed significantly higher prevalences of positive consensus criteria aPL (aCL and a&#x003b2;<sub>2</sub>GPI IgG as well as IgM) in APS patients (<italic>n</italic>&#x02009;=&#x02009;34) compared to HS (<italic>n</italic>&#x02009;=&#x02009;20) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In addition, the LIA revealed significantly more prevalent aPA and aPS IgG as well as IgM, and further aPG IgG, aPI IgG, and aPT IgG in APS patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively).</p></sec><sec id="Sec11"><title>Comparison of qualitative aPL testing in APS patients and disease controls</title><p id="Par23">The comparison of APS patients (<italic>n</italic>&#x02009;=&#x02009;34) with asymptomatic SARD patients (<italic>n</italic>&#x02009;=&#x02009;41) revealed significantly higher prevalences in APS patients for the criteria aPL aCL and a&#x003b2;<sub>2</sub>GPI IgG detected by ELISA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The, frequency of LAC positivity was also significantly elevated in APS, whereas the frequency of triple positivity demonstrated a tendency only (<italic>p</italic>&#x02009;=&#x02009;0.0312, 0.0713, respectively). In terms of aPL testing by LIA, aPG IgG, a&#x003b2;<sub>2</sub>GPI IgG, and aPT IgG as well as aPS IgG and IgM were significantly higher prevalent in patients suffering from APS in contrast to SARD patients. Of note, aPG IgG showed a significantly lower prevalence of 9.8% in asymptomatic SARD patients (4/41) compared to 52.9% in APS patients (18/34, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). The same holds true for aPT IgG with a prevalence of 17.1% in SARD (7/41) vs 50.0% in APS (17/34, <italic>p</italic>&#x02009;=&#x02009;0.0002).</p></sec><sec id="Sec12"><title>Comparison of quantitative aPL testing in APS patients and controls</title><p id="Par24">Quantitative assessment revealed significantly different aPL IgG and IgM levels in the study cohorts regarding all consensus criteria aPL (aCL and a&#x003b2;<sub>2</sub>GPI) by ELISA (Kruskal&#x02013;Wallis, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In terms of LIA testing, IgG and IgM to CL, &#x003b2;<sub>2</sub>GPI, PA, PS, PT, and PG as well as IgM to AnV demonstrated significantly different values (Kruskal&#x02013;Wallis, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Consensus criteria anti-phospholipid antibodies detected by enzyme-linked immunosorbent assays (ELISAs) in 95 subjects including 34 patients with anti-phospholipid syndrome (APS), 41 with systemic autoimmune rheumatic disease (SARD) and no adverse APS events, as well as 20 healthy subjects (children) (HS) as control group. <italic>a&#x003b2;</italic><sub><italic>2</italic></sub><italic>GPI</italic> anti-beta<sub>2</sub>-glycoprotein I, <italic>aCL</italic> anti-cardiolipin</p></caption><graphic xlink:href="13317_2018_106_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par25">Regarding the differentiation of APS patients from asymptomatic SARD patients by consensus criteria ELISA, only aCL and a&#x003b2;<sub>2</sub>GPI IgG revealed significantly different quantitative levels (post hoc analysis, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In addition to aCL and a&#x003b2;2GPI IgG detected by LIA, IgG to PA, PS, PG, PT, and IgM to PS revealed significantly higher levels in APS patients, too (post hoc analysis, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Anti-phospholipid IgG antibodies analyzed by line immunoassay (LIA) in 95 subjects including 34 patients with anti-phospholipid syndrome (APS), 41 systemic autoimmune rheumatic disease (SARD), and no adverse APS events, as well as 20 healthy subjects (children) (HS) as control group. <italic>a&#x003b2;</italic><sub><italic>2</italic></sub><italic>GPI</italic> anti-beta<sub>2</sub>-glycoprotein I, <italic>aCL</italic> anti-cardiolipin, <italic>aPG</italic> anti-phosphatidylglycerol, <italic>aPI</italic> anti-phosphatidylinositol, <italic>aPS</italic> anti-phosphatidylserine, <italic>aPT</italic> anti-prothrombin, <italic>OD</italic> optical density</p></caption><graphic xlink:href="13317_2018_106_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec13"><title>Comparison of the assay performance of aPL detected by ELISA and LIA</title><p id="Par26">To compare the diagnostic performance for the differentiation of APS from SARD, receiver-operating characteristic (ROC) curve analysis was performed for aPL detected by ELISA and LIA (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The ratio of D1 to D4&#x02013;5 reactivity demonstrated the best performance with an area under the curve (AUC) of 0.76 when compared with consensus criteria aPL ELISAs. The AUC of this ratio was significantly higher than the AUCs of aCL and a&#x003b2;<sub>2</sub>GPI IgM (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). However, there was no significant difference in the prevalence of the aD1/aD4&#x02013;5 ratio in APS in contrast to SARD using the cutoff of 1.5 established in another study previously [<xref ref-type="bibr" rid="CR9">9</xref>]. In accordance with the ROC curve analysis for the aD1/aD4&#x02013;5 ratios of this study, a cutoff of 4.6 instead of 1.5 for the optimal differentiation of APS and SARD was required. Applying this new cutoff, there were 21/34 (61.8%) positive APS patients in contrast to 28/43 (82.4%) with the old cutoff of 1.5. Accordingly, the new cutoff lowered the prevalence of positives in the asymptomatic SARD cohort from 26/41 (63.4%) to 5/41 (12.2%). Consequently, the new prevalence of the APS cohort was significantly higher in contrast to the one of the SARD cohorts (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Receiver-operating characteristics curve analysis of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA) and line immunoassay (LIA) in 34 patients with anti-phospholipid syndrome and 41 disease controls without clinical APS symptoms. The ratio of anti-domain 1 (aD1) and D4&#x02013;5 antibody reactivity (aD4&#x02013;5) by ELISA was compared with criteria aPL determined by ELISA (<bold>a</bold>) and aPL IgG by LIA (<bold>b</bold>). <italic>a&#x003b2;</italic><sub><italic>2</italic></sub><italic>GPI</italic> anti-beta<sub>2</sub>-glycoprotein I, <italic>aCL</italic> anti-cardiolipin, <italic>aPG</italic> anti-phosphatidylglycerol, <italic>aPI</italic> anti-phosphatidylinositol, <italic>aPS</italic> anti-phosphatidylserine, <italic>aPT</italic> anti-prothrombin</p></caption><graphic xlink:href="13317_2018_106_Fig4_HTML" id="MO4"/></fig>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Receiver-operating characteristics curve analysis of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA) and line immunoassay (LIA) in 34 patients with anti-phospholipid syndrome and 41 disease controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">aPL</th><th align="left">AUC</th><th align="left">SE</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left" colspan="4">ELISA</td></tr><tr><td align="left">&#x000a0;aD1/aD4&#x02013;5</td><td char="." align="left">0.760</td><td char="." align="left">0.0597</td><td char="&#x02013;" align="char">0.647&#x02013;0.851</td></tr><tr><td align="left">&#x000a0;a&#x003b2;<sub>2</sub>GPI IgG</td><td align="left">0.705</td><td align="left">0.0617</td><td char="&#x02013;" align="char">0.588&#x02013;0.805</td></tr><tr><td align="left">&#x000a0;a&#x003b2;<sub>2</sub>GPI IgM</td><td align="left">0.534*,<sup>$,&#x000a7;</sup></td><td align="left">0.0679</td><td char="&#x02013;" align="char">0.416&#x02013;0.651</td></tr><tr><td align="left">&#x000a0;aCL IgG</td><td align="left">0.725</td><td align="left">0.0598</td><td char="&#x02013;" align="char">0.609&#x02013;0.821</td></tr><tr><td align="left">&#x000a0;aCL IgM</td><td align="left">0.559*,<sup>$,&#x000a7;</sup></td><td align="left">0.0679</td><td char="&#x02013;" align="char">0.440&#x02013;0.674</td></tr><tr><td align="left" colspan="4">LIA</td></tr><tr><td align="left">&#x000a0;a&#x003b2;<sub>2</sub>GPI IgG</td><td char="." align="left">0.691</td><td char="." align="left">0.0638</td><td char="&#x02013;" align="char">0.574&#x02013;0.793</td></tr><tr><td align="left">&#x000a0;aCL IgG</td><td char="." align="left">0.660</td><td char="." align="left">0.0651</td><td char="&#x02013;" align="char">0.541&#x02013;0.765</td></tr><tr><td align="left">&#x000a0;aPS IgG</td><td char="." align="left">0.716<sup>&#x00026;</sup></td><td char="." align="left">0.0613</td><td char="&#x02013;" align="char">0.600&#x02013;0.814</td></tr><tr><td align="left">&#x000a0;aPG IgG</td><td char="." align="left">0.723<sup>&#x00026;</sup></td><td char="." align="left">0.0630</td><td char="&#x02013;" align="char">0.608&#x02013;0.821</td></tr><tr><td align="left">&#x000a0;aPT IgG</td><td char="." align="left">0.701</td><td char="." align="left">0.0628</td><td char="&#x02013;" align="char">0.584&#x02013;0.801</td></tr></tbody></table><table-wrap-foot><p>Area under the curve (AUC) was determined for the ratio of anti-domain 1 of beta<sub>2</sub> glycoprotein I (aD1) and domains 4&#x02013;5 (D4&#x02013;5) antibody reactivity (D4&#x02013;5) by ELISA and compared with those for criteria aPL determined by ELISA and aPL IgG by LIA</p><p><italic>a&#x003b2;</italic><sub><italic>2</italic></sub><italic>GPI</italic> anti-beta<sub>2</sub> glycoprotein I, <italic>aCL</italic> anti-cardiolipin, <italic>aPG</italic> anti-phosphatidyl-glycerol, <italic>aPI</italic> anti-phosphatidylinositol, <italic>aPS</italic> anti-phosphatidyl-serine, <italic>aPT</italic> anti-prothrombin, <italic>CI</italic> confidence interval, <italic>SE</italic> standard error</p><p>AUC comparison of ELISA</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for the comparison to the AUC of the ratio of aD1 to D4&#x02013;5</p><p><sup>$</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for the comparison to the AUC of a&#x003b2;<sub>2</sub>GPI IgG</p><p><sup>&#x000a7;</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for the comparison to the AUC of aCL IgG</p><p>AUC comparison of LIA</p><p><sup>&#x00026;</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for the comparison to the AUC of aCL IgG</p></table-wrap-foot></table-wrap>
</p><p id="Par27">Furthermore, there was no significant difference of the AUC for the aD1/aD4&#x02013;5 ratio to the AUC of aPG IgG detected by LIA. The latter demonstrated in turn the best performance among the aPL IgG determined by LIA and was significantly higher than the AUC of aCL IgG (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In accordance with inter-rater agreement statistics, there was a good agreement for aPG IgG with the aD1/aD4&#x02013;5 ratio [kappa&#x02009;=&#x02009;0.71, 95% confidence interval (CI) 0.52&#x02013;0.89] and no significant difference (McNemar&#x02019;s test: difference&#x02009;=&#x02009;5.3%, 95% CI &#x02212; 6.8 to 15.7%, <italic>p</italic>&#x02009;=&#x02009;0.4807).</p><p id="Par28">In contrast, the strength of agreement of the aD1/aD4&#x02013;5 ratio with all four consensus criteria aPL determined by ELISA was only fair (kappa&#x02009;&#x0003c;&#x02009;0.4, aCL IgM, and a&#x003b2;<sub>2</sub>GPI IgG) or poor (kappa&#x02009;&#x0003c;&#x02009;0.2, a&#x003b2;2GPI IgM, and aCL IgG).</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par29">The persistent occurrence of aPL was the serological hallmark of APS and was defined as a mandatory classification criterion [<xref ref-type="bibr" rid="CR26">26</xref>]. It is a well-accepted consensus that APS-specific aPL interact with phospholipid-binding proteins such as &#x003b2;<sub>2</sub>GPI or complexes thereof with phospholipids. Among aPL, the correlation of a&#x003b2;<sub>2</sub>GPI with clinical symptoms appeared to be the strongest one [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In this context, aPL binding to D1 and not to D4&#x02013;5 of &#x003b2;<sub>2</sub>GPI has been the basis for the detection of disease-specific aPL [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. There has been no single assay to assess all different aPL subpopulations, and thus, aCL, a&#x003b2;<sub>2</sub>GPI, and LAC testing have been recommended to identify all the potential aPL. Triple positivity has been considered a risk factor and could be used for stratification of APS patients [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par30">A novel aPL assay technology employing a hydrophobic membrane for aPL profiling by LIA was reported recently [<xref ref-type="bibr" rid="CR19">19</xref>]. The LIA membrane provided a unique matrix allowing phospholipids to mimic their natural conformation required for co-factor binding as reported for other amphiphatic non-protein antigenic molecules [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. In particular, D1 of patient&#x02019;s serum &#x003b2;<sub>2</sub>GPI appeared to be presented in the LIA reaction environment for APS-specific aPL binding more favorably than the corresponding D4&#x02013;5 after the interaction of serum &#x003b2;<sub>2</sub>GPI with the immobilized phospholipids (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Interestingly, complexes of the patient&#x02019;s &#x003b2;<sub>2</sub>GPI with differing immobilized phospholipids demonstrated different aD1 reactivity. Altogether, this seemed to support the differentiation of disease-specific aPL in APS patients from aPL found in individuals with infectious disease or in asymptomatic carriers [<xref ref-type="bibr" rid="CR16">16</xref>]. Thus, we attempted to ascertain whether this novel reaction environment for the multiplex detection of aPL can discriminate aPL in APS patients from those occurring in patients with other autoimmune disorders like SARD not demonstrating clinical symptoms of APS.</p><p id="Par31">The agreement of aPL testing by LIA with consensus criteria aPL by ELISA was good (IgG aPL) to moderate (IgM aPL) and, thus, was in line with previously published comparative data [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In addition, the favorable specificity of aPL testing by LIA could also be confirmed in this study revealing no significant difference for all ten aPL tested by LIA compared with the four consensus criteria aPL by ELISA.</p><p id="Par32">In terms of the occurrence of aPL in APS patients compared with that in SARD patients without clinical symptoms of APS, only IgG consensus criteria aPL demonstrated a significant difference. Although LAC testing revealed significantly different prevalences too, triple positivity analysis did not differentiate APS patients from those with SARD. Of interest, aPL IgG by LIA also revealed significantly higher prevalences in APS compared to SARD without clinical symptoms of APS. In contrast to aCL IgG by ELISA, however, the difference of aCL IgG by LIA did not reach significance. Of note, aPS testing demonstrated for both immunoglobulin isotypes significantly different prevalences. Provided that the positive aPS result was due to interaction of patient&#x02019;s aPS with serum &#x003b2;<sub>2</sub>GPI of the patient sample having bound to immobilized PS on the LIA membrane, this might add further evidence to the assumption that &#x003b2;<sub>2</sub>GPI binding to negatively charged phospholipids induces specific conformational changes unique for each distinct phospholipid. Since D1 binding by a&#x003b2;<sub>2</sub>GPI was preferred in the LIA reaction environment [<xref ref-type="bibr" rid="CR16">16</xref>], the differing accessibility of respective epitopes on D1 could determine the specificity of such aPL reactivity. Thus, the significantly reduced prevalence of aPG IgG in SARD without clinical symptoms of APS (9.8%) compared to APS (52.9%) in this study is of particular interest in this context. Of note, CL also referred to as diphosphatidylglycerol represents a dimer of PG and CL&#x02019;s head bears two phosphate groups forming a dianion for &#x003b2;<sub>2</sub>GPI binding [<xref ref-type="bibr" rid="CR33">33</xref>]. This particular setting could induce a &#x003b2;<sub>2</sub>GPI configuration enabling sensitive binding of aPL but, obviously, did not provide a reaction environment for the discrimination of aPL occurring in APS and asymptomatic SARD patients. However, quantitative aPL testing did reveal significantly different levels of aCL IgG by LIA like did quantitative aPA, aPS, aPG, and aPT IgG analysis by this method. Of note, quantitative aPS IgM testing did corroborate the significant difference of the qualitative one. In contrast, consensus criteria&#x02019; aPL IgM analysis by ELISA did not reveal significantly different aPL levels in APS and asymptomatic SARD patients. This further highlights the specificity of the LIA reaction environment for aPL analysis and the putative role of differing &#x003b2;<sub>2</sub>GPI configurations for specific aPL binding.</p><p id="Par33">Recently, the ratio of aD1 to aD4&#x02013;5 was reported as a useful marker for APS [<xref ref-type="bibr" rid="CR9">9</xref>]. Surprisingly, the recommended cutoff of aD1/D4&#x02013;5 did not enable differentiating APS from SARD patients in this study. Only after applying ROC curve analysis and readjusting the cut-off to 4.6, significantly different prevalences in both groups were determined. Furthermore, the ROC curve analysis of the aD1/aD4&#x02013;5 ratio revealed the best performance compared with the consensus criteria aPL determined by ELISA.</p><p id="Par34">The assay performance of aPG IgG analysis being the best amongst the aPL detection by LIA was not significantly different from the performance of the aD1/aD4&#x02013;5 ratio. In addition, there was no significant difference and a good agreement between qualitative aPG IgG analysis by LIA and D1/D4&#x02013;5 ratio assessment. Thus, the LIA reaction environment consisting of immobilized PG interacting with the specimen&#x02019;s &#x003b2;<sub>2</sub>GPI might favor the specific binding of aD1 as shown for aPL IgG testing recently (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, a specific conformation of the bound &#x003b2;<sub>2</sub>GPI as a single molecule or of a &#x003b2;2GPI layer could minimize the binding of aD4&#x02013;5 and, thus, bring about the high specificity of aPG analysis. As a fact, aD4&#x02013;5 did not seem to be associated with the APS phenotype [<xref ref-type="bibr" rid="CR7">7</xref>]. A similar LIA reaction environment with CL (diphosphatidylglycerol) instead of PG demonstrated a significantly poorer assay performance which underlines the importance of the phospholipid nature for specific aPL binding.</p><p id="Par35">Our study has certain limitations. The relatively low number of samples results in large confidence interval (CI) in particular regarding the comparison of AUC values by ROC analysis. Furthermore, there could be a selection bias for patients with SARD, since these patients were recruited by a&#x003b2;<sub>2</sub>GPI IgG positivity. We employed research ELISA for aD1 analysis which might differ from the presently available commercial aD1 assays.</p><p id="Par36">In summary, aPG IgG analysis by LIA and assessment of the aD1/aD4&#x02013;5 ratio by ELISA enabled the discrimination of aPL in patients with APS from those with asymptomatic SARD. This finding could be helpful in clinical practice, mainly because patients at risk of adverse APS events could be identified and managed more appropriately by primary prophylaxis and more frequent clinical controls [<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec></body><back><fn-group><fn><p>Cecilia Nalli and Valentina Somma shared first authorship.</p></fn><fn><p>Dirk Roggenbuck and Angela Tincani shared senior authorship.</p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="COI-statement"><sec id="FPar1"><title>Conflict of interest</title><p>DR has a management role and is a shareholder of GA Generic Assays GmbH and Medipan GmbH. Both companies are diagnostic manufacturers. MM is employed at Inova Diagnostics selling autoantibody assays. TB is employed at GA Generic Assays selling autoantibody assays. VS is an employee of Medipan. All the other authors declare that they have no financial competing and non-financial conflicts of interest.</p></sec><sec id="FPar2"><title>Human and animal rights</title><p>The study was approved by the local ethics committee and was conducted in accordance with the Helsinki Declaration of 1964 (revised 2008).</p></sec><sec id="FPar3"><title>Informed consent</title><p>We hereby declare that all the patients were examined in the outpatient clinic at the Division of Rheumatology of the University of Brescia in Italy, and they have all consented to donate their sera for the purpose of this publication. Furthermore, this study was approved by the local ethical committee</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>W</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group><article-title>Antiphospholipid syndrome</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>1498</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60709-X</pub-id><pub-id pub-id-type="pmid">20822807</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Tedesco</surname><given-names>F</given-names></name></person-group><article-title>Pathogenesis of antiphospholipid syndrome: understanding the antibodies</article-title><source>Nat Rev Rheumatol</source><year>2011</year><volume>7</volume><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2011.52</pub-id><pub-id pub-id-type="pmid">21556027</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>DeGroot</surname><given-names>PG</given-names></name><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Boffa</surname><given-names>MC</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Kamashta</surname><given-names>MA</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><article-title>Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines</article-title><source>Lupus</source><year>2003</year><volume>12</volume><fpage>530</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1191/0961203303lu394oa</pub-id><pub-id pub-id-type="pmid">12892393</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Amengual</surname><given-names>O</given-names></name><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Chighizola</surname><given-names>CB</given-names></name><name><surname>Forastiero</surname><given-names>R</given-names></name><name><surname>deGroot</surname><given-names>P</given-names></name><name><surname>Lakos</surname><given-names>G</given-names></name><name><surname>Lambert</surname><given-names>M</given-names></name><name><surname>Meroni</surname><given-names>P</given-names></name><name><surname>Ortel</surname><given-names>TL</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Roubey</surname><given-names>R</given-names></name><name><surname>Sciascia</surname><given-names>S</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Tebo</surname><given-names>AE</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Willis</surname><given-names>R</given-names></name></person-group><article-title>14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends</article-title><source>Autoimmun Rev</source><year>2014</year><volume>13</volume><fpage>917</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2014.05.001</pub-id><pub-id pub-id-type="pmid">24824074</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebo</surname><given-names>AE</given-names></name><name><surname>Willis</surname><given-names>R</given-names></name><name><surname>Jaskowski</surname><given-names>TD</given-names></name><name><surname>Guerra</surname><given-names>M</given-names></name><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>Salmon</surname><given-names>J</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>DW</given-names></name></person-group><article-title>Clinical significance and correlations between anti-beta2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus</article-title><source>Clin Chim Acta</source><year>2016</year><volume>460</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2016.06.025</pub-id><pub-id pub-id-type="pmid">27346478</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalli</surname><given-names>C</given-names></name><name><surname>Piantoni</surname><given-names>S</given-names></name><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Motta</surname><given-names>M</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name></person-group><article-title>Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin</article-title><source>Isr Med Assoc J</source><year>2012</year><volume>14</volume><fpage>310</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">22799064</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Nalli</surname><given-names>C</given-names></name><name><surname>Motta</surname><given-names>M</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><name><surname>Shums</surname><given-names>Z</given-names></name><name><surname>Encabo</surname><given-names>S</given-names></name><name><surname>Binder</surname><given-names>WL</given-names></name><name><surname>Nuzzo</surname><given-names>M</given-names></name><name><surname>Frassi</surname><given-names>M</given-names></name><name><surname>Lojacono</surname><given-names>A</given-names></name><name><surname>Avcin</surname><given-names>T</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name></person-group><article-title>Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their &#x02018;innocent&#x02019; profile?</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>380</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.137281</pub-id><pub-id pub-id-type="pmid">20971718</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>deLaat</surname><given-names>B</given-names></name><name><surname>Derksen</surname><given-names>RH</given-names></name><name><surname>Urbanus</surname><given-names>RT</given-names></name><name><surname>DeGroot</surname><given-names>PG</given-names></name></person-group><article-title>IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>1540</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-09-3387</pub-id><pub-id pub-id-type="pmid">15507529</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Chighizola</surname><given-names>CB</given-names></name><name><surname>Nalli</surname><given-names>C</given-names></name><name><surname>Gerosa</surname><given-names>M</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Pregnolato</surname><given-names>F</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><name><surname>Zanola</surname><given-names>A</given-names></name><name><surname>Allegri</surname><given-names>F</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name></person-group><article-title>Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2-glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome</article-title><source>Arthritis Rheumatol</source><year>2015</year><volume>67</volume><fpage>2196</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1002/art.39187</pub-id><pub-id pub-id-type="pmid">25939498</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattia</surname><given-names>E</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name><name><surname>Meneghel</surname><given-names>L</given-names></name><name><surname>Tonello</surname><given-names>M</given-names></name><name><surname>Faggian</surname><given-names>D</given-names></name><name><surname>Hoxha</surname><given-names>A</given-names></name><name><surname>Fredrigo</surname><given-names>M</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name></person-group><article-title>A contribution to detection of anticardiolipin and anti-beta2glycoprotein I antibodies: comparison between a home-made ELISA and a fluorescence enzyme immunoassay</article-title><source>Clin Chim Acta</source><year>2015</year><volume>446</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.04.012</pub-id><pub-id pub-id-type="pmid">25892672</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Khamashta</surname><given-names>M</given-names></name></person-group><article-title>Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome</article-title><source>Autoimmun Rev</source><year>2012</year><volume>12</volume><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2012.05.006</pub-id><pub-id pub-id-type="pmid">22652408</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fickentscher</surname><given-names>C</given-names></name><name><surname>Magorivska</surname><given-names>I</given-names></name><name><surname>Janko</surname><given-names>C</given-names></name><name><surname>Biermann</surname><given-names>M</given-names></name><name><surname>Bilyy</surname><given-names>R</given-names></name><name><surname>Nalli</surname><given-names>C</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Medeghini</surname><given-names>V</given-names></name><name><surname>Meini</surname><given-names>A</given-names></name><name><surname>Nimmerjahn</surname><given-names>F</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>LE</given-names></name><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name></person-group><article-title>The pathogenicity of anti-&#x003b2;2GP1-IgG autoantibodies depends on Fc glycosylation</article-title><source>J Immunol Res</source><year>2015</year><volume>2015</volume><fpage>638129</fpage><pub-id pub-id-type="doi">10.1155/2015/638129</pub-id><pub-id pub-id-type="pmid">26185769</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Albesa</surname><given-names>R</given-names></name><name><surname>Zohoury</surname><given-names>N</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Ateka-Barrutia</surname><given-names>O</given-names></name><name><surname>Rodriguez-Garcia</surname><given-names>JL</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><name><surname>Khamashta</surname><given-names>M</given-names></name></person-group><article-title>Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome</article-title><source>Lupus</source><year>2016</year><volume>25</volume><fpage>911</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1177/0961203316640366</pub-id><pub-id pub-id-type="pmid">27252269</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meneghel</surname><given-names>L</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name><name><surname>Gavasso</surname><given-names>S</given-names></name><name><surname>Meneghel</surname><given-names>L</given-names></name><name><surname>Tonello</surname><given-names>M</given-names></name><name><surname>Salvan</surname><given-names>E</given-names></name><name><surname>Pengo</surname><given-names>V</given-names></name><name><surname>Punzi</surname><given-names>V</given-names></name></person-group><article-title>Detection of IgG anti-domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome</article-title><source>Clin Chim Acta</source><year>2015</year><volume>446</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.04.033</pub-id><pub-id pub-id-type="pmid">25935129</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name></person-group><article-title>APS ACTION-antiphospholipid syndrome alliance for clinical trials and international networking</article-title><source>Lupus</source><year>2012</year><volume>21</volume><fpage>695</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1177/0961203312437810</pub-id><pub-id pub-id-type="pmid">22635205</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Somma</surname><given-names>V</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>T</given-names></name><name><surname>Schierack</surname><given-names>P</given-names></name><name><surname>Hanack</surname><given-names>K</given-names></name><name><surname>Grossi</surname><given-names>C</given-names></name><name><surname>Bodio</surname><given-names>C</given-names></name><name><surname>Macor</surname><given-names>P</given-names></name><name><surname>von Landenberg</surname><given-names>P</given-names></name><name><surname>Boccellato</surname><given-names>F</given-names></name><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group><article-title>Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers</article-title><source>Arthritis Res Ther</source><year>2016</year><volume>18</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s13075-016-1018-x</pub-id><pub-id pub-id-type="pmid">27209064</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Biggioggero</surname><given-names>M</given-names></name><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>Sheldon</surname><given-names>J</given-names></name><name><surname>Zegers</surname><given-names>I</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name></person-group><article-title>Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases</article-title><source>Nat Rev Rheumatol</source><year>2014</year><volume>10</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2013.180</pub-id><pub-id pub-id-type="pmid">24275965</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pengo</surname><given-names>V</given-names></name><name><surname>Biasiolo</surname><given-names>A</given-names></name><name><surname>Pegoraro</surname><given-names>C</given-names></name><name><surname>Cucchini</surname><given-names>U</given-names></name><name><surname>Noventa</surname><given-names>F</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name></person-group><article-title>Antibody profiles for the diagnosis of antiphospholipid syndrome</article-title><source>Thromb Haemost</source><year>2005</year><volume>93</volume><fpage>1147</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1160/TH04-12-0839</pub-id><pub-id pub-id-type="pmid">15968401</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Egerer</surname><given-names>K</given-names></name><name><surname>von Landenberg</surname><given-names>P</given-names></name><name><surname>Hiemann</surname><given-names>R</given-names></name><name><surname>Feist</surname><given-names>E</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>D&#x000f6;rner</surname><given-names>T</given-names></name></person-group><article-title>Antiphospholipid antibody profiling&#x02014;time for a new technical approach</article-title><source>Autoimmun Rev</source><year>2012</year><volume>11</volume><fpage>821</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2012.02.016</pub-id><pub-id pub-id-type="pmid">23006529</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoxha</surname><given-names>A</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name><name><surname>Mattia</surname><given-names>E</given-names></name><name><surname>Meneghel</surname><given-names>L</given-names></name><name><surname>Tonello</surname><given-names>M</given-names></name><name><surname>Salvan</surname><given-names>E</given-names></name><name><surname>Pengo</surname><given-names>V</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name></person-group><article-title>Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome</article-title><source>Clin Chem Lab Med</source><year>2015</year><volume>53</volume><fpage>1265</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1515/cclm-2014-1129</pub-id><pub-id pub-id-type="pmid">25562605</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egerer</surname><given-names>K</given-names></name><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Buettner</surname><given-names>T</given-names></name><name><surname>Lehmann</surname><given-names>B</given-names></name><name><surname>Kohn</surname><given-names>A</given-names></name><name><surname>von Landenberg</surname><given-names>P</given-names></name><name><surname>Hiemann</surname><given-names>R</given-names></name><name><surname>Feist</surname><given-names>E</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>D&#x000f6;rner</surname><given-names>T</given-names></name></person-group><article-title>Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay</article-title><source>Arthritis Res Ther</source><year>2011</year><volume>13</volume><fpage>R118</fpage><pub-id pub-id-type="doi">10.1186/ar3421</pub-id><pub-id pub-id-type="pmid">21777436</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Egerer</surname><given-names>K</given-names></name><name><surname>Feist</surname><given-names>E</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name></person-group><article-title>Antiphospholipid antibody profiling&#x02014;association with the clinical phenotype in APS?</article-title><source>Arthritis Rheum</source><year>2012</year><volume>64</volume><fpage>2807</fpage><lpage>2808</lpage><pub-id pub-id-type="doi">10.1002/art.34545</pub-id><pub-id pub-id-type="pmid">22614803</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Somma</surname><given-names>V</given-names></name><name><surname>Schierack</surname><given-names>P</given-names></name><name><surname>Borghi</surname><given-names>MO</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group><article-title>Autoantibody profiling in APS</article-title><source>Lupus</source><year>2014</year><volume>23</volume><fpage>1262</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1177/0961203314534305</pub-id><pub-id pub-id-type="pmid">25228721</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pengo</surname><given-names>V</given-names></name></person-group><article-title>ISTH guidelines on lupus anticoagulant testing</article-title><source>Thromb Res</source><year>2012</year><volume>130</volume><issue>Suppl 1</issue><fpage>S76</fpage><lpage>S77</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2012.08.283</pub-id><pub-id pub-id-type="pmid">23026672</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devreese</surname><given-names>KM</given-names></name><name><surname>Pierangeli</surname><given-names>SS</given-names></name><name><surname>de Laat</surname><given-names>Tripodi A</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Ortel</surname><given-names>TL</given-names></name></person-group><article-title>Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH</article-title><source>J Thromb Haemost</source><year>2014</year><volume>12</volume><fpage>792</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1111/jth.12537</pub-id><pub-id pub-id-type="pmid">24589091</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Branch</surname><given-names>DW</given-names></name><name><surname>Brey</surname><given-names>RL</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Derksen</surname><given-names>RH</given-names></name><name><surname>de Groot</surname><given-names>PG</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name><name><surname>Reber</surname><given-names>G</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Vlachoyiannopoulos</surname><given-names>PG</given-names></name><name><surname>Krilis</surname><given-names>SA</given-names></name></person-group><article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title><source>J Thromb Haemost</source><year>2006</year><volume>4</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01753.x</pub-id><pub-id pub-id-type="pmid">16420554</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group><article-title>Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools</article-title><source>Lupus</source><year>2016</year><volume>25</volume><fpage>905</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1177/0961203316641772</pub-id><pub-id pub-id-type="pmid">27252268</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pengo</surname><given-names>V</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name><name><surname>Tonello</surname><given-names>M</given-names></name><name><surname>Cuffaro</surname><given-names>S</given-names></name><name><surname>Banzato</surname><given-names>A</given-names></name><name><surname>Bison</surname><given-names>E</given-names></name><name><surname>Denas</surname><given-names>G</given-names></name><name><surname>Padayattil Jose</surname><given-names>S</given-names></name></person-group><article-title>Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk</article-title><source>J Thromb Haemost</source><year>2015</year><volume>13</volume><fpage>782</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1111/jth.12865</pub-id><pub-id pub-id-type="pmid">25645395</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pengo</surname><given-names>V</given-names></name><name><surname>Banzato</surname><given-names>A</given-names></name><name><surname>Denas</surname><given-names>G</given-names></name><name><surname>Jose</surname><given-names>SP</given-names></name><name><surname>Bison</surname><given-names>E</given-names></name><name><surname>Hoxha</surname><given-names>A</given-names></name><name><surname>Ruffatti</surname><given-names>A</given-names></name></person-group><article-title>Correct laboratory approach to APS diagnosis and monitoring</article-title><source>Autoimmun Rev</source><year>2013</year><volume>12</volume><fpage>832</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2012.11.008</pub-id><pub-id pub-id-type="pmid">23219767</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenherr</surname><given-names>G</given-names></name><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>S</given-names></name><name><surname>Porstmann</surname><given-names>T</given-names></name></person-group><article-title>Technical problems arising from the use of the immunoblot for determination of the reactivity of natural antibodies with different lipopolysaccharides (LPS)</article-title><source>J Immunol Methods</source><year>1996</year><volume>190</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(95)00271-5</pub-id><pub-id pub-id-type="pmid">8621953</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Schoenherr</surname><given-names>G</given-names></name><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Marx</surname><given-names>U</given-names></name><name><surname>von Baehr</surname><given-names>R</given-names></name></person-group><article-title>Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria</article-title><source>Hybridoma</source><year>1996</year><volume>15</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1089/hyb.1996.15.191</pub-id><pub-id pub-id-type="pmid">8823616</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>K</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Ziemssen</surname><given-names>T</given-names></name><name><surname>Talaska</surname><given-names>T</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>Humbel</surname><given-names>RL</given-names></name><name><surname>Roggenbuck</surname><given-names>D</given-names></name></person-group><article-title>A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies</article-title><source>Ann N Y Acad Sci</source><year>2007</year><volume>1109</volume><fpage>256</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1196/annals.1398.031</pub-id><pub-id pub-id-type="pmid">17785314</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathappa</surname><given-names>M</given-names></name><name><surname>Alder</surname><given-names>NN</given-names></name></person-group><article-title>The ionization properties of cardiolipin and its variants in model bilayers</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1858</volume><fpage>1362</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2016.03.007</pub-id><pub-id pub-id-type="pmid">26965987</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chighizola</surname><given-names>CB</given-names></name><name><surname>Ubiali</surname><given-names>T</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group><article-title>Treatment of thrombotic antiphospholipid syndrome: the rationale of current management&#x02014;an insight into future approaches</article-title><source>J Immunol Res</source><year>2015</year><volume>2015</volume><fpage>951424</fpage><pub-id pub-id-type="doi">10.1155/2015/951424</pub-id><pub-id pub-id-type="pmid">26075289</pub-id></element-citation></ref></ref-list></back></article>